[1] Antonello A., Tarozzi A., Morroni F., Cavalli A., Rosini M., Hrelia P., Bolognesi M.L., Melchiorre C.,
Multitarget-Directed Drug Design Strategy: A Novel Molecule Designed to Block Epidermal Growth Factor Receptor (EGFR) and to Exert Proapoptotic Effects,
J. Med. Chem.,
49(23):6642-6645 (2006).
[3] Torre L.A., Bray F., Siegel R.L., Ferlay J., Lortet-Tieulent J., Jemal A.,
Global Cancer Statistics, 2012,
CA Cancer J. Clin.,
65(2):87-108 (2015).
[5] Yinhua D., Foroughi M.M., Aramesh-Boroujeni Z., Jahani S., Peydayesh M., Borhani F., Khatami M., Rohani M., Dusek M., Eigner V.,
The Synthesis, Characterization, DNA/BSA/HSA Interactions, Molecular Modeling, Antibacterial Properties, and In Vitro Cytotoxic Activities of Novel Parent and Niosome Nano-Encapsulated Ho (III) Complexes,
RSC Adv.,
10(39): 22891-22908 (2020).
[6] Aliabadi A., Afnanzade N.-S., Hosseinzadeh L., Mohammadi-Farani A., Shafiee M.H., Nazari H., Ahmadi F., Foroumadi A.R.,
N-(5-(Trifluoromethyl)-1, 3, 4-Thiadiazol-2-yl) Benzamide and Benzothioamide Derivatives Induce Apoptosis via Caspase-Dependent Pathway,
Pharm. Chem. J.,
53(6): 521-526 (2019).
[8] Li S., Guo C., Sun X., Li Y., Zhao H., Zhan D., Lan M., Tang Y.,
Synthesis and Biological Evaluation of Quinazoline and Quinoline Bearing 2, 2, 6, 6-Tetramethylpiperidine-N-Oxyl as Potential Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors and EPR Bio-Probe Agents,
Eur. J. Med. Chem.,
49: 271-278 (2012).
[13] Garofalo A., Goossens L., Lemoine A., Ravez S., Six P., Howsam M., Farce A., Depreux P.,
[4-(6, 7-Disubstituted Quinazolin-4-ylamino) Phenyl] Carbamic Acid Esters: A Novel Series of Dual EGFR/VEGFR-2 Tyrosine Kinase Inhibitors,
MedChemComm,
2(1): 65-72 (2011).
[14] Sini P., Wyder L., Schnell C., O'Reilly T., Littlewood A., Brandt R., Hynes N.E., Wood J.,
The Antitumor and Antiangiogenic Activity of Vascular Endothelial Growth Factor Receptor Inhibition is Potentiated by ErbB1 Blockade,
Clin. Cancer Res.,
11(12): 4521-4532 (2005).
[16] Xu P., Chu J., Li Y., Wang Y., He Y., Qi C., Chang J.,
Novel Promising 4-Anilinoquinazoline-Based Derivatives as Multi-Target RTKs Inhibitors: Design, Molecular Docking, Synthesis, and Antitumor Activities In Vitro and Vivo,
Bioorg. Med. Chem.,
27(20): 1-8 (2019).
[17] Ismail R.S.M., Abou-Seri S.M., Eldehna W.M., Ismail N.S.M., Elgazwi S.M., Ghabbour H.A., Ahmed M.S., Halaweish F.T., Abou El Ella D.A.,
Novel Series of 6-(2-Substitutedacetamido)-4-Anilinoquinazolines as EGFR-ERK Signal Transduction Inhibitors in MCF-7 Breast Cancer Cells,
Eur. J. Med. Chem.,
155:782-796 (2018).
[18] Wei H., Duan Y., Gou W., Cui J., Ning H., Li D., Qin Y., Liu Q., Li Y.,
Design, Synthesis and Biological Evaluation of Novel 4-Anilinoquinazoline Derivatives as Hypoxia-Selective EGFR and VEGFR-2 Dual Inhibitors,
Eur. J. Med. Chem.,
181(1):1-12 (2019).
[19] Hennequin L.F., Stokes E.S., Thomas A.P., Johnstone C., Plé P.A., Ogilvie D.J., Dukes M., Wedge S.R., Kendrew J., Curwen J.O.,
Novel 4-Anilinoquinazolines with C-7 Basic Side Chains: Design and Structure-Activity Relationship of a Series of Potent, Orally Active, VEGF Receptor Tyrosine Kinase Inhibitors,
J. Med. Chem.,
45(6):1300-1312 (2002).
[20] Hennequin L.F., Thomas A.P., Johnstone C., Stokes E.S., Plé P.A., Lohmann J.-J.M., Ogilvie D.J., Dukes M., Wedge S.R., Curwen J.O., Kendrew J., van der Brempt Ch.L.,
Design and Structure−Activity Relationship of a New Class of Potent VEGF Receptor Tyrosine Kinase Inhibitors,
J. Med. Chem.,
42(26):5369-5389 (1999).
[23] Zhao M., Wang L., Zheng L., Zhang M., Qiu C., Zhang Y., Du D., Niu B.,
2D-QSAR and 3D-QSAR Analyses for EGFR Inhibitors,
Biomed Res. Int., 2017 (2017).
[25] Heydari Alizadeh B., Vosooghi M., Khoobi M., Javidnia A., Panah F., Safavi M., Adrestani S., Shafiee A.,
Synthesis and Cytotoxic Activity of Novel 9-[Hydroxy (Substituted Phenyl) Methyl]-2, 2-Dimethyl-2, 3, 8, 9-Tetrahydro-4H, 10H-Pyrano
[2, 3-f] Chromene-4, 10-Diones,
Iran. J. Chem. Chem. Eng. (IJCCE),
29(4):189-196 (2010).
[26] Holladay M.W., Campbell B.T., Rowbottom M.W., Chao Q., Sprankle K.G., Lai A.G., Abraham S., Setti E., Faraoni R., Tran L., Armstrong R.C., Gunawardane R.N., Gardner M.F., Cramer M.D., Gitnick D., Ator M.A., Dorsey B.D., Ruggeri B.R., James J.,
4-Quinazolinyloxy- diaryl Ureas as Novel BRAFV600E Inhibitors,
Bioorg. Med. Chem.,
21(18): 5342-5346 (2011).
[27] Mozaffari S., Ghasemi S., Baher H., Khademi H., Amini M., Sakhteman A., Foroumadi A., Ebrahimabadi A.H., Sharifzadeh M.,
Synthesis and Evaluation of some Novel methylene-bridged Aryl Semicarbazones as Potential Anticonvulsant Agents,
Medicinal Chemistry Research,
21(11): 3797-3808 (2012).
[28] Zhang N., Wu B., Powell D., Wissner A., Floyd M.B., Kovacs E.D., Toral-Barza L., Kohler C.,
Synthesis and Structure–Activity Relationships of 3-cyano-4-(phenoxyanilino) Quinolines as MEK (MAPKK) Inhibitors,
Bioorg. Med. Chem.,
10(24): 2825-2828 (2000).
[30] Zhang Y., Gao H., Liu R., Liu J., Chen L., Li X., Zhao L., Wang W., Li B.,
Quinazoline-1-deoxynojirimycin Hybrids as High Active Dual Inhibitors of EGFR and α-glucosidase,
Bioorg. Med. Chem.,
27(18): 4309-4313 (2017).
[31] Garofalo A., Farce A., Ravez S.v., Lemoine A.l., Six P., Chavatte P., Goossens L., Depreux P.,
Synthesis and Structure-Activity relationships of (aryloxy) quinazoline Ureas as Novel, Potent, and Selective Vascular Endothelial Growth Factor Receptor-2 Inhibitors,
J. Med. Chem.,
55(3):1189-1204 (2012).
[39] Zuo K., Qian J., Gong J., Zhang J., Li H., Zhou G.,
Synthesis, Characterization, Molecular Docking and Cytotoxicity Studies of Bagasse Xylem Ferulate-Acrylamide/Methyl Methacrylate Composite,
Iran. J. Chem. Chem. Eng. (IJCCE),
38(3):107-116 (2019).
[41] Robichaux J.P., Elamin Y.Y., Tan Z., Carter B.W., Zhang S., Liu S., Li Sh., Chen T., Pottete A., Estrada-Bernal A., Le A.T., Truini A., Nilsson M.B., Sun H., Roarty E., Goldberg S.B., Brahmer J.R., Altan M., Lu Ch., Papadimitrakopoulou V., Politi K., Doebele R.C., Wong K.K., Heymach J.V.,
Mechanisms and Clinical Activity of an EGFR and HER2 Exon 20–Selective Kinase Inhibitor in Non–Small Cell Lung Cancer,
Nat. Med.,
24(5): 638-646 (2018).
[43] Aramesh-Boroujeni Z., Bordbar A.-K., Khorasani-Motlagh M., Fani N., Sattarinezhad E., Noroozifar M.,
Computational and Experimental Study on the Interaction of Three Novel Rare Earth Complexes Containing 2, 9-Dimethyl-1, 10-Phenanthroline with Human Serum Albumin,
J. Iran. Chem. Soc.,
15(7): 1581-1591 (2018).
[44] Aramesh-Boroujeni Z., Jahani S., Khorasani-Motlagh M., Kerman K., Noroozifar M.,
Evaluation of Parent and Nano-Encapsulated Terbium (III) Complex toward its Photoluminescence Properties, FS-DNA, BSA Binding Affinity, and Biological Applications,
J. Trace Elem. Med. Biol., 126564 (2020).